Ovarian Cancer — Trials, FDA Actions & Pivotal Research
15 updates aggregated from openFDA and ClinicalTrials.gov, covering trial milestones, FDA actions, and pivotal publications about Ovarian Cancer.
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
Drugs with Ovarian Cancer trials
Recruiting trials by city
Cities where Ovarian Cancer trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.
Updates
2026
- Primary completionOvarian Cancer Trial Completes Phase 3 Primary Data Collection· May 3, 2026
- Results postedNivolumab Trial Results Posted for Ovarian, Fallopian Tube, Peritoneal Cancer· Apr 1, 2026· drug: Nivolumab
- Results postedPembrolizumab Combination Trial for Solid Tumors Reports DLTs at High Dose· Mar 27, 2026· drug: Pembrolizumab
- Results postedPembrolizumab Improves PFS in Platinum-Resistant Recurrent Ovarian Cancer· Mar 9, 2026· drug: Pembrolizumab
- Results postedPembrolizumab/NT-I7 Combination Shows Dose-Dependent TEAEs in Solid Tumors· Feb 9, 2026· drug: Pembrolizumab
- Results postedOvarian Cancer: Acupressure Trial Results Posted for Fatigue Management· Feb 5, 2026
2025
- Results postedHOPE-Genomics Trial Results Posted for Cancer Patient Education· Dec 11, 2025
- Results postedPembrolizumab Combination Trial for Advanced Solid Tumors Terminated· Nov 17, 2025· drug: Pembrolizumab
- Results postedPembrolizumab/Lenvatinib Combo Shows Up to 77.4% DCR in Ovarian Cancer· Nov 17, 2025· drug: Pembrolizumab
- Results postedBreast Cancer: Patients Spend 404 Minutes/Week on Care Tasks· Sep 16, 2025
- Results postedPembrolizumab/Olaparib Combo Extends PFS in Advanced Ovarian Cancer· Sep 12, 2025· drug: Pembrolizumab
- Results postedPembrolizumab Combination Trial for Platinum-Resistant Ovarian Cancer Terminated· Aug 28, 2025· drug: Pembrolizumab
- Results postedCancer Patients' Treatment Priorities Posted for Elderly and Young· Jul 1, 2025
- Results postedNivolumab in Ovarian Cancer: Combination with Rucaparib Reduces PFS· Jun 24, 2025· drug: Nivolumab
- Results postedBreast Cancer: Tailored Counseling Boosts Genetic Risk Assessment Uptake· May 28, 2025